Home » Stocks » Abbott Laboratories

Abbott Laboratories (ABT)

Stock Price: $103.45 USD 2.53 (2.51%)
Updated Sep 25, 2020 4:02 PM EDT - Market closed
After-hours: $103.35 -0.10 (-0.10%) Sep 25, 7:56 PM

Stock Price Chart

Key Info

Market Cap 183.16B
Revenue (ttm) 31.44B
Net Income (ttm) 3.11B
Shares Out 1.77B
EPS (ttm) 1.73
PE Ratio 59.80
Forward PE 23.15
Dividend $1.44
Dividend Yield 1.39%

Stock Quote

Trading Day Sep 25, 2020
Last Price $103.45
Previous Close $100.92
Change ($) 2.53
Change (%) 2.51%
Day's Open 100.48
Day's Range 100.34 - 103.61
Day's Volume 5,060,317
52-Week Range 61.61 - 114.20

More Stats

Market Cap 183.16B
Enterprise Value 197.80B
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date Jul 14, 2020
Shares Outstanding 1.77B
Float 1.76B
EPS (basic) 1.75
EPS (diluted) 1.73
FCF / Share 2.57
Dividend $1.44
Dividend Yield 1.39%
Earnings Yield 1.67%
FCF Yield 2.49%
Payout Ratio n/a
Shares Short 8.68M
Short Ratio 1.32
Short % of Float 0.50%
Beta 0.95
PE Ratio 59.80
Forward PE 23.15
P/FCF Ratio 40.13
PS Ratio 5.83
PB Ratio 5.84
Revenue 31.44B
Operating Income 4.02B
Net Income 3.11B
Free Cash Flow 4.56B
Net Cash -14.64B
Net Cash / Share -8.27
Gross Margin 59.50%
Operating Margin 12.78%
Profit Margin 9.90%
FCF Margin 14.51%
ROA 4.01%
ROE 9.86%
ROIC 12.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (21)

Buy 14
Overweight 2
Hold 3
Underweight 1
Sell 1

Analyst Consensus: Buy

Price Target

(11.71% upside)
Current: $103.45
Target: 115.56
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth4.34%11.64%31.35%2.2%0.78%3%3.19%-11.01%-39.13%-
Gross Profit18,67317,87214,98111,75911,65811,02910,46410,15111,39020,502
Operating Income4,5323,6501,5643,0262,8672,5992,1331,3601,6296,088
Net Income3,6872,3684771,4004,4232,2842,5765,9634,7284,626
Shares Outstanding1,7681,7581,7401,4771,4961,5161,5581,5751,5571,546
Earnings Per Share2.061.330.270.942.921.491.623.723.012.96
EPS Growth54.89%392.59%-71.28%-67.81%95.97%-8.02%-56.45%23.59%1.69%-
Dividend Per Share1.
Dividend Growth14.29%5.66%1.92%8.33%9.09%-97.5%1651.74%6.91%9.3%-
Operating Cash Flow6,1366,3005,5703,2032,9663,6753,3249,3148,9708,736
Capital Expenditures-1,638-1,394-1,135-1,121-1,110-1,077-1,145-1,795-1,491-1,015
Free Cash Flow4,4984,9064,4352,0821,8562,5982,1797,5197,4797,721
Cash & Equivalents4,1404,0869,61018,7756,1254,4608,09815,1748,0977,324
Total Debt18,13919,56627,92422,0069,0017,8306,56120,47615,41518,918
Net Cash / Debt-13,999-15,480-18,314-3,231-2,876-3,3701,537-5,302-7,317-11,594
Book Value31,30130,72231,09820,71721,32621,63925,26726,81324,52622,765
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Abbott Laboratories
Country United States
Employees 107,000
CEO Robert B. Ford

Stock Information

Ticker Symbol ABT
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: ABT


Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.